Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05703425
PHASE2

The Effect of Sulfasalazine on CRH Levels in Pregnant Women

Sponsor: Rutgers, The State University of New Jersey

View on ClinicalTrials.gov

Summary

The goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are: * Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a prior history of preterm birth? * Does sulfasalazine reduce the incidence of recurrent preterm birth in pregnant persons given drug vs. controls? Consenting participants will be randomized to receive sulfasalazine or to a control group and will undergo serial blood draws to assess plasma CRH levels.

Official title: The Effect of Sulfasalazine on CRH Levels in Pregnant Women With a History of Pre-Term Birth: A Randomized Controlled Trial

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

50

Start Date

2023-03-01

Completion Date

2026-06-30

Last Updated

2025-09-22

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Sulfasalazine

Sulfasalazine will be administered between 24 and 36 weeks of pregnancy

Locations (1)

Rutgers Robert Wood Johnson Medical School

New Brunswick, New Jersey, United States